Skip to content
OpenCapital
Get started

Adaptive Biotechnologies ADPT Q1 2026 earnings

Reported May 5, 2026 · After market close

Revenue$70.9MBeat by $9.9M
EPS-$0.13Beat by $0.03
Revenue estimate$61.0M
EPS estimate-$0.16

Next report

Date not yet announced

Financials

Q1 2026

Income statement

See full
Revenue$70.9M+35.1%
Gross profit$52.2M+47.1%
Operating income-$19.2M+35.1%
Net income-$20.0M+32.9%
EPS (diluted)-$0.13+35.0%

Balance sheet

See full
Cash & equivalents$77.6M+53.2%
Total debt$208.2M-5.6%
Total equity$216.3M+13.6%
Total assets$505.9M-1.0%

Cash flow

See full
Operating cash flow-$9.5M+66.5%
CapEx$796.0K-36.8%
Free cash flow-$10.3M+65.3%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$3.61B+124%
Enterprise value$3.74B+109%
P/S12.2×+4.4×

Profitability

See full
Gross margin75.3%+12.7pp
Operating margin-15.8%-7.0pp
Net margin-16.8%-7.3pp
FCF margin-10.5%-4.6pp

Returns & leverage

See full
Return on equity-24.4%-9.2pp
Debt / equity1×-0.2×
Current ratio3.4×+0.4×

Segments

By product

See full
Service$58.1M+48.1%
Regulatory Milestone Revenue$9.0M+100%
Service And Licensing Revenue$3.8M—
Collaboration Revenue--100%

By segment

See full
Mrd Business$67.1M+53.5%
Immune Medicine Business$3.8M-56.6%

Versus estimates

Revenue

Q1 2026$70.9MBeat by $9.9M
Q4 2025$71.7MBeat by $10.8MQ3 2025$94.0MBeat by $34.6MQ2 2025$58.9MBeat by $3.5MQ1 2025$52.4MBeat by $10.3MQ4 2024$47.5MBeat by $1.4M

Diluted EPS

Q1 2026-$0.13Beat by $0.03
Q4 2025-$0.09Beat by $0.10Q3 2025-$0.15Beat by $0.01Q2 2025-$0.17Beat by $0.07Q1 2025-$0.20Beat by $0.08Q4 2024-$0.23Beat by $0.04

Ask the moment Adaptive Biotechnologies reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Adaptive Biotechnologies report Q1 2026 earnings?
Adaptive Biotechnologies (ADPT) reported Q1 2026 earnings on May 5, 2026 after market close.
What were Adaptive Biotechnologies's Q1 2026 revenue and EPS?
Adaptive Biotechnologies reported revenue of $70.9M and eps of $-0.13 for Q1 2026.
Did Adaptive Biotechnologies beat estimates in Q1 2026?
Revenue beat the consensus estimate of $61.0M by $9.9M. EPS beat the consensus estimate of $-0.16 by $0.03.
How did Adaptive Biotechnologies's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 35.2% from $52.4M a year earlier and eps grew 35.0% from $-0.20.
Where can I find Adaptive Biotechnologies's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-206455) and the 10-Q periodic report (0001193125-26-206546) directly on SEC EDGAR. The filing index links above go to sec.gov.